TheraRadar
Data updated: May 26, 2026

ADQUEY (difamilast)

Dermatology Approved 2026-02-12

1 INDICATIONS & USAGE ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

Source: FDA Label • ACROTECH BIOPHARMA
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-02-12
Patent Cliff
2036

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
OINTMENT

Companies

Active Ingredient: DIFAMILAST

ADQUEY Approval History

Original
New Indication
New Form
Label Update
1 FDA actions from 2026 to 2026
Feb 2026 ORIGINAL
New Drug · Type 1 - New Molecular Entity

What ADQUEY Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT05608343 MM36-301 Ph 3 completed This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
NCT05571943 MM36-302 Ph 3 completed A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADQUEY FDA Label Details

Indications & Usage

FDA Label (PDF)

1 INDICATIONS & USAGE ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

ADQUEY Patents & Exclusivity

Latest Patent: Dec 2036
Exclusivity: Feb 2031

Patents (2 active)

US10588893 Expires Dec 31, 2036
USRE46792 Expires Mar 1, 2028

Exclusivity

NCE Until Feb 2031
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ADQUEY

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2036
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.